Company Profile:

Vaxcyte, Inc. (Nasdaq: PCVX) is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). The Company is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and our exclusively licensed XpressCFTM cell-free protein synthesis platform. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine program designed to prevent Shigella. The Company is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.

Vaxcyte, headquartered in San Carlos, CA, went public in June 2020 and currently has a team of approximately 180 employees and anticipates continued, significant growth. Following equity offerings in October 2022 and April 2023, which generated over $1.1 billion in net proceeds, the Company’s balance sheet is further strengthened to advance its pipeline of novel vaccines, including VAX-24. These financings followed positive data readouts from Vaxcyte’s Phase 1/2 proof-of-concept study evaluating VAX-24 in adults aged 18-64 and Phase 2 study in adults 65 and older. The Company believes these results support a best-in-class potential for VAX-24, which was designed to replace the current standard-of-care in adults and children. VAX-24 is being investigated for the prevention of IPD, which can be most serious for infants, young children, older adults and those with immune deficiencies or certain chronic health conditions. Given the global impact of pneumococcal disease remains significant, the public health community continues to advocate for vaccines that can offer broader protection to prevent IPD. Vaxcyte’s PCV franchise, consisting of VAX-24 and VAX-31, is designed specifically to address this need and has the potential to deliver the broadest protection for this very serious disease. We believe that our PCVs could receive regulatory approval based on successful completion of clinical studies utilizing well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies.

Summary:

We are seeking a motivated candidate to join our Pilot Plant operations team and support the design, construction, commissioning, and operation of a new state-of-the-art facility. This facility will serve as a major technical hub of the business and will support execution of process characterization, validation studies as well as new technology evaluations as deemed necessary. Once the facility is online, you'll be responsible for routine pilot plan operations as well as contribute towards future plant expansion projects. The position will provide an opportunity for learning and development in a professional lab setting, contributing to development and commercialization of our company's life-saving therapeutics. The primary responsibility for this position will be the support of the pilot plant operations team with secondary opportunities to support the MSAT team.

The ideal candidate should have experience with small - scale and/or large - scale bioprocess equipment, including stainless steel and single use mixing tanks, bioreactors, sterile filtration, chromatography systems, aseptic technique and be able to work well with others, communicate effectively both written and orally. Candidates may be requested to work during non-business hours/days to support extended growth and production activities.

Essential Functions:

• Actively support routine pilot plant operations.
• Batch documentation within an electronic laboratory system.
• Participate in scheduling discussions within the operations team.
• Work collaboratively with process development scientists, MSAT colleagues and external partners as necessary.
• Support safety and training initiatives.
• Employs good housekeeping and helps manage materials supply chain as required for seamless PP operations.

• BS in Chemical/Biochemical/Biomedical Engineering/Biology/Chemistry or related discipline with 2 year of relevant experience (5 for Sr. Scientist).
• Strong skills in laboratory experimentation and documentation.
• Strong communication and interpersonal skills to work in cross-functional team environments.
• Lead technical projects or sub-teams including vendor interactions.
• Strong troubleshooting skills.
• Ability and willingness to learn new lab techniques, adhere to all safety guidelines, and pick up/move up 25lbs.
• Basic computer skills including Microsoft Office with proficiency in Power App, Power BI, Word, and Excel.
• All Vaxcyte employees require vaccination against COVID-19.

Reports to: Director, Protein Development and Clinical Manufacturing

Location: San Carlos, CA

Compensation:

The compensation package will be competitive and includes comprehensive benefits and an equity component.

Salary Range: $150,000 – $170,000

Send resumes to:

careers@vaxcyte.com

Vaxcyte, Inc.

825 Industrial Road, Suite 300

San Carlos, CA 94070

We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.